Macroscopic Portal Vein Thrombosis in HCC Patients

Basit Öğe Kaydı
dc.authoridAkkiz, Hikmet/0000-0001-9745-8875
dc.authoridCarr, Brian/0000-0002-6111-5077
dc.authoridEKIN, NAZIM/0000-0001-5302-8953
dc.authoridALTINTAS, ENGIN/0000-0003-0796-1456
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridSonsuz, Abdullah/0000-0002-8336-5472
dc.authoridTokmak, Salih/0000-0002-2727-5632
dc.contributor.authorAkkiz, Hikmet
dc.contributor.authorCarr, Brian I.
dc.contributor.authorKuran, Sedef
dc.contributor.authorKaraogullarindan, Umit
dc.contributor.authorUskudar, Oguz
dc.contributor.authorTokmak, Salih
dc.contributor.authorArslan, Burcu
dc.date.accessioned2024-09-18T21:06:28Z
dc.date.available2024-09-18T21:06:28Z
dc.date.issued2018
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractMacroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD <5cm to 56.4% with tumors of MTD >10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumormultifocality. A logistic regressionmodel that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD >5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.en_US
dc.description.sponsorshipNIH [CA 82723]en_US
dc.description.sponsorshipThis work is supported in part by NIH Grant CA 82723 (Brian I. Carr)Yen_US
dc.identifier.doi10.1155/2018/3120185
dc.identifier.issn2291-2789
dc.identifier.issn2291-2797
dc.identifier.pmid30009156en_US
dc.identifier.scopus2-s2.0-85049358746en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1155/2018/3120185
dc.identifier.urihttps://hdl.handle.net/20.500.12483/13627
dc.identifier.volume2018en_US
dc.identifier.wosWOS:000436297600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHindawi Ltden_US
dc.relation.ispartofCanadian Journal of Gastroenterology and Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGamma-Carboxy Prothrombinen_US
dc.subjectUnresectable Hepatocellular-Carcinomaen_US
dc.subjectAutologous Growth-Factoren_US
dc.subjectComputed-Tomographyen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectAlpha-Fetoproteinen_US
dc.subjectVenous Invasionen_US
dc.subjectTumoren_US
dc.subjectSurvivalen_US
dc.subjectUltrasounden_US
dc.titleMacroscopic Portal Vein Thrombosis in HCC Patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
1.59 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu